Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $58.6 million.

  • Adma Biologics' Cost of Revenue fell 262.88% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.3 million, marking a year-over-year increase of 1318.29%. This contributed to the annual value of $206.9 million for FY2024, which is 2222.92% up from last year.
  • As of Q3 2025, Adma Biologics' Cost of Revenue stood at $58.6 million, which was down 262.88% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Cost of Revenue ranged from a high of $60.2 million in Q3 2024 and a low of $700000.0 during Q2 2023
  • Over the past 5 years, Adma Biologics' median Cost of Revenue value was $40.4 million (recorded in 2023), while the average stood at $36.8 million.
  • Per our database at Business Quant, Adma Biologics' Cost of Revenue crashed by 9732.17% in 2023 and then surged by 700542.86% in 2024.
  • Over the past 5 years, Adma Biologics' Cost of Revenue (Quarter) stood at $22.9 million in 2021, then soared by 56.54% to $35.8 million in 2022, then rose by 19.59% to $42.8 million in 2023, then rose by 26.62% to $54.2 million in 2024, then rose by 8.08% to $58.6 million in 2025.
  • Its Cost of Revenue was $58.6 million in Q3 2025, compared to $54.8 million in Q2 2025 and $53.7 million in Q1 2025.